• 1
    Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 116137.
  • 2
    Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, Ohuchi K, Kawaguchi H, Ishikawa Y, Ishii T, Uematsu S, Akira S, Murakami M, Kudo I. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J Biol Chem 2004; 279: 3368495.
  • 3
    Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 2003; 100: 90449.
  • 4
    Friesen RW, Mancini JA. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem 2008; 51: 405967.
  • 5
    Xu D, Rowland SE, Clark P, Giroux A, Cote B, Guiral S, Salem M, Ducharme Y, Friesen RW, Methot N, Mancini J, Audoly L, Riendeau D. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008; 326: 75463.
  • 6
    Kawahara H, Sakamoto A, Takeda S, Onodera H, Imaki J, Ogawa R. A prostaglandin E2 receptor subtype EP1 receptor antagonist (ONO-8711) reduces hyperalgesia, allodynia, and c-fos gene expression in rats with chronic nerve constriction. Anesth Analg 2001; 93: 10127.
  • 7
    Mebane H, Turnbach ME, Randich A. Spinal EP receptors mediating prostaglandin E2-induced mechanical hyperalgesia, thermal hyperalgesia, and touch-evoked allodynia in rats. J Pain 2003; 4: 3929.
  • 8
    Minami T, Nakano H, Kobayashi T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Ito S. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol 2001; 133: 43844.
  • 9
    Omote K, Kawamata T, Nakayama Y, Kawamata M, Hazama K, Namiki A. The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain. Anesth Analg 2001; 92: 2338.
  • 10
    Omote K, Yamamoto H, Kawamata T, Nakayama Y, Namiki A. The effects of intrathecal administration of an antagonist for prostaglandin E receptor subtype EP(1) on mechanical and thermal hyperalgesia in a rat model of postoperative pain. Anesth Analg 2002; 95: 170812.
  • 11
    Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, Kim HS, Flannery PJ, Coffman TM, McNeish JD, Audoly LP. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001; 107: 32531.
  • 12
    Syriatowicz JP, Hu D, Walker JS, Tracey DJ. Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience 1999; 94: 58794.
  • 13
    Giblin GM, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessell IP, Clayton NM, Coleman T, Hall A, Hammond B, Hurst DN, Michel AD, Naylor A, Novelli R, Scoccitti T, Spalding D, Tang SP, Wilson AW, Wilson R. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 2007; 17: 3859.
  • 14
    Hall A, Billinton A, Giblin GM. EP1 antagonists for the treatment of inflammatory pain. Curr Opin Drug Discov Devel 2007; 10: 597612.
  • 15
    Hall A, Brown SH, Budd C, Clayton NM, Giblin GM, Goldsmith P, Hayhow TG, Hurst DN, Naylor A, Anthony Rawlings D, Scoccitti T, Wilson AW, Winchester WJ. Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain. Bioorg Med Chem Lett 2009; 19: 497501.
  • 16
    Hall A, Billinton A, Brown SH, Chowdhury A, Clayton NM, Giblin GM, Gibson M, Goldsmith PA, Hurst DN, Naylor A, Peet CF, Scoccitti T, Wilson AW, Winchester W. Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 2009; 19: 2599603.
  • 17
    Hall A, Brown SH, Chessell IP, Chowdhury A, Clayton NM, Coleman T, Giblin GM, Hammond B, Healy MP, Johnson MR, Metcalf A, Michel AD, Naylor A, Novelli R, Spalding DJ, Sweeting J, Winyard L. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives. Bioorg Med Chem Lett 2007; 17: 91620.
  • 18
    Wilson AW, Medhurst SJ, Dixon CI, Bontoft NC, Winyard LA, Brackenborough KT, De Alba J, Clarke CJ, Gunthorpe MJ, Hicks GA, Bountra C, McQueen DS, Chessell IP. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain 2006; 10: 53749.
  • 19
    Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. eds Brunton LL, Lazo JS, Parker KL. New York: The McGraw-Hill Companies, 2005; 1787888.
  • 20
    Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007; 81: 246.
  • 21
    Ings RM. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 2009; 1: 1293305.
  • 22
    Lappin G, Garner RC. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 2008; 4: 1499506.
  • 23
    Lewis LD. Early human studies of investigational agents: dose or microdose? Br J Clin Pharmacol 2009; 67: 2779.
  • 24
    Harrison A, Gardner I, Hay T, Dickins M, Beaumont K, Phipps A, Purkins L, Allan G, Christian R, Duckworth J, Gurrell I, Kempshall S, Savage M, Seymour M, Simpson M, Taylor L, Turnpenny P. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica 2012; 42: 5774.
  • 25
    European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose (CPMP, SWP, 2599, 02, Rev 1, London). 23 June 2004. Available at (last accessed 19 May 2012).
  • 26
    FDA. Guidance for Industry Investigators and Reviewrs. Exploratory IND Studies. Washington, DC: Food and Drug Administration UdoHaHS, 2006. Available at (last accessed 19 May 2012).
  • 27
    European Microdosing AMS Partnership Programme (EUMAPP). Outcomes from EUMAPP – a study comparing in vitro, in silcico, microdose and pharmacology dose pharmacokinetics. 2008. Available at (last accessed 19 May 2012).
  • 28
    Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to phase 0 trials. Br J Cancer 2007; 97: 57781.
  • 29
    Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006; 80: 20315.
  • 30
    Yamane N, Takami T, Tozuka Z, Sugiyama Y, Yamazaki A, Kumagai Y. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab Pharmacokinet 2009; 24: 389403.
  • 31
    Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B 2007; 858: 11828.
  • 32
    Madan A, O'Brien Z, Wen J, O'Brien C, Farber RH, Beaton G, Crowe P, Oosterhuis B, Garner RC, Lappin G, Bozigian HP. A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009; 67: 28898.
  • 33
    Hayton WL, Hu T. Allometric scaling. In: Preclinical Development Handbook: ADME and Biopharmaceutical Properties, ed. Gad SC. Haboken, NJ: John Wiley & Sons, Inc., 2008; 100936.
  • 34
    Mahmood I. Interspecies scaling of clearance. In: Interspecies Pharmacokinetic Scaling, Principles and Application of Allometric Scaling, 1st edn, ed. Mahmood I. Rockville, MD: Pine House Publishers, 2005; 3985.
  • 35
    Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 117792.
  • 36
    Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 2005; 33: 128893.
  • 37
    Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 2007; 35: 188693.
  • 38
    Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 2004; 32: 6129.
  • 39
    Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004; 32: 60311.
  • 40
    Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93: 252234.
  • 41
    Jolivette LJ, Ward KW. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: molecular properties associated with extrapolative success or failure. J Pharm Sci 2005; 94: 146783.
  • 42
    Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54: 95101.
  • 43
    Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 14771.
  • 44
    Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 1997; 86: 58490.
  • 45
    Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 131624.
  • 46
    Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003; 31: 5808.
  • 47
    Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS, Lee FW, Miwa GT. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006; 34: 3848.
  • 48
    McLean MA, Tam CJ, Baratta MT, Holliman CL, Ings RM, Galluppi GR. Accelerating drug development: methodology to support first-in-man pharmacokinetic studies by the use of drug candidate microdosing. Drug Dev Res 2007; 68: 1422.
  • 49
    Mahajan R, Parvez A, Gupta K. Microdosing vs. therapeutic dosing for evaluation of pharmacokinetic data: a comparative study. J Young Pharm 2009; 1: 2904.
  • 50
    Sugiyma Y, Yamashita S. Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev 2010; 63: 494502.
  • 51
    Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75: 102840.
  • 52
    Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 4658.
  • 53
    Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker Inc., 1982.